Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial

Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial

Show other versions (1)

Background<br/> Anti-angiogenic agents have an established role in the treatment of metastatic colorectal cancer (CRC). It was hypothesised that their effectiveness may be augmented in earlier stage disease with a more malleable vasculature. The QUASAR 2 trial examined whether bevacizumab coul...

Full description

Bibliographic Details
Main Authors: Love, S, Kerr, R, Segelov, E, Johnstone, E, Falcon, B, Hewett, P, Weaver, A, Church, D, Scudder, C, Pearson, S, Julier, P, Pezzella, F, Tomlinson, I, Domingo, E, Kerr, D
Format: Journal article
Published: Lancet 2016

Similar Items